BioAge Labs, Inc.: first participant dosed in QUELL-DME phase 2

What happened BioAge Labs, Inc. announced on Oct 2, 2026 that the first participant has been dosed in QUELL-DME, a randomized, controlled phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (DME).

Key details

• The trial is randomized, controlled, three-arm and will enroll approximately 180 participants with 12 weeks of once-daily dosing and a four-week follow-up.
• Participants are randomized 1:1:1 into (i) intravitreal anti-VEGF plus oral placebo, (ii) intravitreal anti-VEGF plus BGE-102 90 mg daily, and (iii) sham intravitreal injection plus BGE-102 90 mg daily.
• The primary endpoint is change in best-corrected visual acuity at week 12; exploratory endpoints include retinal parameters and intraocular and plasma biomarkers.
• Topline results are expected in the second half of 2027; the filing says results are expected to inform development in other NLRP3-driven retinal diseases, including geographic atrophy.

Why it may matter Item 8.01 was reported. Item 8.01 covers other events, and here the company reported clinical trial dosing and trial design details for its QUELL-DME phase 2 study. This filing does not show why the insider traded or why the company acted.